Jiangsu Rongtai Biotech

Jiangsu Rongtai Biotechnology is a Chinese biotechnology company specializing in the development of therapeutic radiopharmaceuticals and providing comprehensive R&D services for biological macromolecules. The company's lead clinical candidate, 188Re-HEDP (Rhenium [188Re] etidronate), is a bone-seeking radiopharmaceutical currently in Phase 2 clinical trials for the treatment of bone metastases in patients with prostate and lung cancer. Beyond its internal pipeline, Jiangsu Rongtai operates several technology platforms for recombinant protein expression, mammalian cell line construction, and high-throughput antibody production, serving both academic and industrial partners. Headquartered in Nanjing with facilities in Changzhou, the company integrates research, production, and technical services to support the development of innovative biologics and nuclear medicine.